跳至主要内容
临床试验/DRKS00028582
DRKS00028582已完成不适用

Prophylaxis Impact on Quality of Life Impariment of HAE Patients with Lower Annual Base Attack Rates - PIQHAR

Takeda GmbH0 个研究点目标入组 22 人开始时间: 2022年3月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Takeda GmbH
入组人数
22

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
12 Years 至 one(—)
性别
All

入选标准

  • Confirmed diagnosis of HAE Type 1/2.
  • - Voluntarily provision of written, signed, and dated (personally or via a legally authorized representative) informed consent to participate in the study.
  • - Initiation of treatment with lanadelumab in accordance with current product labelling.
  • - Documented history of = 24 attacks in the year prior to enrollment AND baseline AE-QoL Score of = 30 points.
  • - 12 years or older.

排除标准

  • - Inability to provide written, signed, and dated informed consent.
  • - Documented history of > 24 confirmed HAE attacks/year in the year prior to study enrollment OR baseline AE-QoL Score of < 30 points.
  • - Participation in the study ruled out by the treating physician/investigator.
  • - Pregnant or breastfeeding.
  • - Current or planned participation in interventional studies.

研究者

发起方
Takeda GmbH

相似试验